These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8269948)

  • 1. A drug-resistant variant of topoisomerase II alpha in human HL-60 cells exhibits alterations in catalytic pH optimum, DNA binding and sub-nuclear distribution.
    Boege F; Kjeldsen E; Gieseler F; Alsner J; Biersack H
    Eur J Biochem; 1993 Dec; 218(2):575-84. PubMed ID: 8269948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-sensitivity and DNA-binding of a subform of topoisomerase II alpha in resistant human HL-60 cells.
    Boege F; Biersack H; Meyer P
    Acta Oncol; 1994; 33(7):799-806. PubMed ID: 7993649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II.
    Zwelling LA; Hinds M; Chan D; Mayes J; Sie KL; Parker E; Silberman L; Radcliffe A; Beran M; Blick M
    J Biol Chem; 1989 Oct; 264(28):16411-20. PubMed ID: 2550442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform.
    Harker WG; Slade DL; Drake FH; Parr RL
    Biochemistry; 1991 Oct; 30(41):9953-61. PubMed ID: 1655025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells.
    Bakic M; Chan D; Andersson BS; Beran M; Silberman L; Estey E; Ricketts L; Zwelling LA
    Biochem Pharmacol; 1987 Dec; 36(23):4067-77. PubMed ID: 2825713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of anion-exchange chromatography and chromatofocusing to reveal the structural and functional heterogeneity of topoisomerase II in a HL-60 cell line resistant to multi-drug treatment.
    Boege F; Gieseler F; Biersack H; Clark M
    J Chromatogr; 1991 Nov; 587(1):3-9. PubMed ID: 1664428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interaction between nuclear topoisomerase II activity from human leukemia cells, exogenous DNA, and 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) or 4-(4,6-O-ethylidene-beta-D-glucopyranoside) (VP-16) indicates the sensitivity of the cells to the drugs.
    Estey EH; Silberman L; Beran M; Andersson BS; Zwelling LA
    Biochem Biophys Res Commun; 1987 Apr; 144(2):787-93. PubMed ID: 3034264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Further characterization of an amsacrine-resistant line of HL-60 human leukemia cells and its topoisomerase II. Effects of ATP concentration, anion concentration, and the three-dimensional structure of the DNA target.
    Mayes J; Hinds M; Soares L; Altschuler E; Kim P; Zwelling LA
    Biochem Pharmacol; 1993 Aug; 46(4):699-707. PubMed ID: 8395843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different functional states of topoisomerase II can be discriminated by orthovanadate sensitivity in multi-drug resistant human leukemic cells.
    Boege F; Gieseler F; Biersack H; Meyer P
    Leuk Lymphoma; 1993 Mar; 9(4-5):381-3. PubMed ID: 8394170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S; Benchokroun Y; Larsen AK
    Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development.
    Zwelling LA; Mitchell MJ; Satitpunwaycha P; Mayes J; Altschuler E; Hinds M; Baguley BC
    Cancer Res; 1992 Jan; 52(1):209-17. PubMed ID: 1309224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions.
    Zwelling LA; Mayes J; Hinds M; Chan D; Altschuler E; Carroll B; Parker E; Deisseroth K; Radcliffe A; Seligman M
    Biochemistry; 1991 Apr; 30(16):4048-55. PubMed ID: 1850298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
    Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
    Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered drug interaction and regulation of topoisomerase IIbeta: potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposide.
    Grabowski DR; Holmes KA; Aoyama M; Ye Y; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
    Mol Pharmacol; 1999 Dec; 56(6):1340-5. PubMed ID: 10570063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations at arg486 and glu571 in human topoisomerase IIalpha confer resistance to amsacrine: relevance for antitumor drug resistance in human cells.
    Patel S; Keller BA; Fisher LM
    Mol Pharmacol; 2000 Apr; 57(4):784-91. PubMed ID: 10727526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
    Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
    Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
    Ellis AL; Nowak B; Plunkett W; Zwelling LA
    Cancer Chemother Pharmacol; 1994; 34(3):249-56. PubMed ID: 8004759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
    Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
    Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo etoposide-resistant C6 glioma cell line: significance of altered DNA topoisomerase II activity in multi-drug resistance.
    Taki T; Ohnishi T; Arita N; Hiraga S; Hayakawa T
    J Neurooncol; 1998 Jan; 36(1):41-53. PubMed ID: 9525824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The measurement of nuclear topoisomerase II inhibition in vitro: a possible tool for detecting resistance on a subcellular level in haematopoietic malignancies.
    Boege F; Gieseler F; Biersack H; Meyer P
    Eur J Clin Chem Clin Biochem; 1992 Feb; 30(2):63-8. PubMed ID: 1316175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.